Education

• MD, University of Virginia School of Medicine, Charlottesville, VA, 1989
• Junior Residency in General Surgery, University of Chicago, Chicago, IL, 1989-1990
• Residency in Urology, University of Chicago, Chicago, IL, 1990-1994
• Fellow in Urologic Oncology, American Foundation for Urologic Disease, Johns Hopkins University, Baltimore, MD, 1994-1996

Clinical Specialties

Dr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment including robotics.

Research Interests

Dr. Jarrard has a joint appointment with the University of Wisconsin Comprehensive Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health to examine genetic and epigenetic alterations in prostate cancer.

Dr. Jarrard's lab

Funding/Grants

• The Induction of Cellular Senescence as Therapy for Advanced Prostate Cancer
  Funding Agency: Prostate Cancer Foundation
  Principal Investigator(s): David F Jarrard, MD
  More Information

Recent Publications

• Laurila TA, Huang W, Jarrard DF. Robotic-assisted laparoscopic and radical retropubic prostatectomy generate similar positive margin rates in low and intermediate risk patients. Urol. Oncol. 2009 Sep-Oct; 27(5):529-33.
  [PubMed ID: 18640061]
  More Information
• Sterrett SP, Jarrard DF. Robotic assisted laparoscopic radical prostatectomy: evolution and outcomes. Minerva Urol Nefrol 2008 Mar; 60(1):31-9.
  [PubMed ID: 18427433]
  More Information
• Sterrett S, Laurila T, Bandi G,and Jarrard DF. Identification and preservation of accessory pudendal vessels during robot-assisted laparoscopic radical prostatectomy. Journal of Robotic Surgery 2008; ():1863-2483.
  More Information
• Allen GW, Howard AR, Jarrard DF, Ritter MA. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer 2007 Oct 1; 110(7):1405-16.
  [PubMed ID: 17685384]
  More Information
• Wong GW, Palazzi-Churas KL, Jarrard DF, Paolone DR, Graf AK, Hedican SP, Wegenke JD, Ritter MA. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 2008 Feb 1; 70(2):449-55.
  [PubMed ID: 17869014]
  More Information